Joff Masukawa

 
Joff-Masukawa.jpg

Board Member

LinkedIn 

Mr. Joff Masukawa is President and Founder of Diligentia, LLC, a life-sciences consultancy that develops commercial business strategies and tactical commercialization requirements for manufacturers of rare orphan and specialty drugs, cell and gene therapies, and other novel emerging medical innovations. Serving as virtual chief commercial officer supporting new product planning for clients, Joff can lead strategy implementation for small organizations and offers complementary government and public affairs capability.

Before founding Diligentia, Joff was Vice President and Global Head of Government Relations and Public Affairs at Shire, where he designed and led strategies to build the company's brand, engagement and leadership with government representatives and agencies, patient advocacy groups, payors, industry associations and other key external stakeholders.

Joff has held senior-level leadership roles spanning commercial and corporate functions, including market access, government and public affairs, patient and provider services, and sales and marketing at Shire, Genzyme, Visible Genetics, Gentiva, and LabCorp. He has developed and executed numerous launch strategies for first-in-class products and services and is an expert at developing and aligning optimal legislative, regulatory and market access solutions to support business objectives. He began as a clinical sales representative for Merck.

He serves on the Board of Directors of Caregiver Action Network, The Center for Healthcare Innovation, and ICORD, the International Conference on Rare Diseases and Orphan Drugs. Joff is also an adjunct instructor at the George Washington School of Medicine and Health Sciences in the Department of Clinical Research and Leadership.

He holds a BA in international studies from Johns Hopkins University and completed his graduate studies in international affairs at the Johns Hopkins School of International Studies and in strategic communications at Columbia University.